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1. Introduction
1.1. Dealing with the burden
World-wide, approximately 410,000 of the estimated 1 million females diagnosed annually
with breast cancer will die from the disease [1]. According to Canadian Cancer Statistics, breast
cancer continues to be the most commonly diagnosed cancer among Canadian women over
the age of 20 (excluding non-melanoma skin cancer) and is the second leading cause of cancer
deaths [2]. In 2012, it was estimated that 22,700 Canadian women would be diagnosed with
breast cancer and 5,200 would succumb to the disease [2]. Furthermore, the recently published
Prince Edward Island (PEI) Cancer Trends Report outlining cancer cases diagnosed from 1980
to 2009 indicates that in PEI, breast cancer is the most commonly diagnosed cancer in women
[3]. While the overall incidence rate of breast cancer has increased marginally (0.5% per annum)
and mortality rates have stabilized since 1992, the long-term survival in PEI women is
significantly lower than the Canadian rate [3]. In summary, breast cancer continues to be a
world-wide issue requiring attention. Increased awareness and advanced screening, resulting
in early detection, is attributed to the increased incidence of the disease and such factors have
led to a high percentage (approximately 95%) of all breast cancer patients being initially
diagnosed with curable disease [4]. However, 30-40% of patients diagnosed with curable breast
cancer succumb to disease reoccurrence [5]. Although increased diagnosis and advances in the
treatment of breast cancer are clearly contributing factors in disease progression, eradication
of residual malignancies and metastatic tumors via a systemic approach is considered the key
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for success in treating cancer and increasing cancer patient survival [6]. There is an urgent need
to explore agents that will be effective in preventing and treating metastasis of breast tumors.
1.2. The biology of breast cancer
In general, cancer occurs when a normal cell accumulates genetic and/or epigenetic changes
caused by the activation or amplification of oncogenes and/or the mutation or loss of tumor
suppressor function, resulting in the ability to proliferate indefinitely [7]. While these specific
alterations lead to the transformation of the normal cell and partly determine the characteri‐
zation of the tumor, the cell of origin and tumor (micro-) environment are also considered
important factors contributing to tumor cell establishment, progression and therapeutic
resistance [8].
2. Clinical characteristics and classification of breast cancer
2.1. Classifying breast cancer
Breast cancer classifications are largely explained by differences in tumor characteristics as
determined by tumor appearance, histology, tumor marker expression (immunohistochemis‐
try) or receptor status, and gene expression profiles. Alone, or in combination, these aspects
can influence treatment, response and prognosis.
2.1.1. Histology
Breast cancer represents many different histologies, however the majority (estimated to be
more than 85%) of breast cancers are collectively derived from the epithelium lining in the
ducts or lobes, and are classified as mammary ductal or lobular carcinoma [9]. Furthermore,
this classification can be defined as in situ (meaning the proliferation of cancer cells within the
epithelial tissue without invasion of the surrounding tissue) or invasive whereby the surround‐
ing tissue is affected [9]. Included in the histological description of breast cancer is the status
of invasion to the perineural and/or lymphovascular space and the presence of such is
associated with more aggressive disease [10].
2.1.2. Grade
Tumor grade is determined by comparing differentiation in normal and cancerous breast
tissues. Normal cells in the breast become differentiated and acquire specific shapes and forms
that reflect their function as part of the mammary system [9]. When cell division becomes
uncontrolled, differentiation is lost. Breast cancers are either well differentiated (low grade),
moderately differentiated (intermediate grade), or poorly differentiated (high grade) [9]. This
progressive loss of features seen in normal breast cells is indicative of disease progression and
poorly differentiated or high grade cancers have a worse prognosis than others [11].
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2.1.3. Stage
Between 1943 and 1952, Pierre Denoix devised the TNM staging systems for all solid tumors
to classify the progression of cancer [12]; the acronym can be explained by the fact that this
model utilizes the size and extension of the primary tumor (T), its spread to the lymph nodes
(N), and the presence of metastases (M). Although it is not utilized for all cancers (i.e.: brain
and spinal cord cancer), the TNM system has progressed to the 7th textbook edition (TNM
Classification of Malignant Tumors) [12] and remains the major system by which breast cancer
is staged. An increase in stage number is based on larger tumor size, nodal spread (in particular,
the sentinel node*) and metastasis and is positively correlated with a worse prognosis [13, 14].
* Certain cancers spread in a predictable manner, from the site of origin to nearby lymph nodes (lymph glands) and then
to other parts of the body. The very first draining lymph node is termed the “sentinel node” and is important in the
sentinel lymph node biopsy (SLNB) technique utilized to stage the spread of certain types of cancer. The absence of cancer
within the sentinel lymph node indicates that there is a high likelihood that the cancer has not spread to any other area
of the body. Lymph node metastasis is considered one of the most important predictive signs in breast cancer, and thus
can serve to guide the surgeon/oncologist to the appropriate therapy.
2.2. Receptor status and gene expression profiles
Recent progress in molecular technologies has led to distinct breast cancer categories and five
distinct tumor types and a normal breast-like group have been identified to date based on gene
expression profiling [15], as summarized in Table 1.
Molecular Sub-type based on Gene
Expression Profiling
Receptor Status based on Immunohistochemistry Reference
Luminal A ER+ve and/or PR+ve, Her2−ve, any CK5/6/Her1 [15-17]
Luminal B ER+ve and/or PR+ve, Her2+ve, any CK5/6/Her1 [15-17]
Basal-like (triple –ive) ER−ve, PR−ve, Her2−ve, CK5,6+ve and/or Her1+ [18]
Her-2+over-expressing (ERBB2) ER−ve, PR−ve, Her2+ve, any CK5/6/Her1 [19]
Normal Breast –like “unclassified” (negative for all 5 markers), displays
putative-initiating stem cell phenotype
[20, 21]
“claudin-low” group “unclassified” (negative for all 5 markers), displays
putative-initiating stem cell phenotype,
Often triple negative, displays low expression of cell-cell
junction proteins and e-cadherin, frequently infiltration
with lymphocytes
[20, 22]
Positive (+ve), negative (−ve), estrogen receptor (ER), progesterone receptor (PR), human epidermal growth factor
receptors (EGFR) 1 and 2 (Her 1 and 2) and cytokeratin 5, 6 (CK5,6).
Table 1. Distinct Molecular Tumor Categories of Breast Cancer and their Receptor Status
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However, most investigators use the presence (+) or absence (-) of immunohistochemical (IHS)
markers or receptor combinations that are expressed by neoplastic cells. In this manner,
distinct tumor categories to-date are identified by the expression of estrogen receptors (ER),
progesterone receptors (PR), human epidermal growth factor receptors (EGFR) 1 and 2 (Her
1 and 2) and cytokeratin 5, 6 (CK5,6) [15-19, 23-25]. Generally, molecular sub-types correspond
to IHC receptor status [26]. These subtypes are of great clinical and research importance as
they are utilized to administer and target therapeutic regimes based on predictions of response.
Furthermore, these subtypes have been shown to display a wide variety of responses to
different treatments [27-30] and are associated with other clinical outcomes, such as patient
relapse and overall survival. The most favorable outcomes are noted for the luminal A subtype,
which are hormone sensitive [31]. The Her2+ and basal subtypes are noted as more aggressive
and have fewer therapeutic options [31-33]. The normal-like and claudin-low are unclassified
(negative for all major receptors), and associated with poor prognosis [20-22, 30, 34]. Several
small studies support the concept that molecular subtype and tumor receptor status may
change during ordinary disease progression and a major study completed by MacFarlane et
al. in 2008 revealed that 21% of relapsed tumors had changes in either ER/PR or HER2 receptor
status [35]. This significant proportion led the author to suggest that biopsies of relapsed/
metastatic breast cancers should be performed routinely. This also should be an important
consideration in research. In summary, treatment options considered effective in primary stage
cancer may no longer be optimal in later stages of the disease, including relapses and metastasis
as determined by the current classification scheme.
2.3. Other classification approaches
Other breast cancer classification approaches are also used to assist in both prognostic and
treatment decisions. These include computer models that are based on a combination of several
factors and offer individual survival predictions and calculations of treatment benefits [36].
For example, patients undergoing systemic adjuvant therapy can determine optimal treatment
through the commercially available computer model Adjuvant which has been successfully
validated in several cohorts, including the United States and Canada [36, 37]. Other useful
classification tools utilized for breast cancer treatment choices include prognostic assessments
(such as USC/Van Nuys prognostic index (VNPI)) and general comorbidity assessments [38,
39]. Also consider the case of familial breast cancer (genetic classification) whereby a patient
may opt to undergo preventative measures such as mastectomy. Additionally, immunohisto‐
chemistry testing, other than those mentioned earlier, continue to prove favorable as prog‐
nostic markers across various molecular subtypes [40]. For example, in human breast cancer
epithelial cell proliferation is considered a significant prognostic marker [41] and could
possibly be used as a prediction tool to measure different hormone treatment related risks [42].
Therefore, the immunohistochemical marker, Ki67 (a nuclear protein expressed by cells in all
active phases of the cycle except for quiescent or resting cells) is utilized frequently to evaluate
proliferation [43]. Such labeling indicates a significant association with higher carcinoma
grade, clinical response to endocrine therapy, higher risk of relapse, and worse survival in
patients with early breast cancer [44].
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3. Cell of origin
While scientists have predicted that specific breast cancer types may arise from different types
of progenitor cells, it has been difficult to identify the cells of origin, and the topic remains
controversial to date. Breast tumors represent a heterogeneous collection of cell populations
with different biological properties [45]. Shared molecular features have made it difficult to
distinguish the cell populations of breast cancer tumors and only recently have researchers
been able to differentiate stem cells from other progenitor cells. Within this context, tumor
evolution has been explained by two main theories. The traditional clonal evolution model is
based on the premise that all tumor cells have the capacity to undergo self-renewal which is
an indication of their potential to undergo tumor progression and drug resistance [46, 47]. The
Cancer Stem Cell (CSC) theory emphasizes the ability of only a minor population of tumori‐
genic cells capable of self-renewal and differentiation [20, 48] and this specific sub-set of CSC’s
gives rise to new tumors which are phenotypically identical to the original tumors [49]. CSC’s
are believed to be a small population of cells with dysregulated self–renewal properties capable
of continuous self-renewal and differentiation and responsible for tumor existence treatment
resistance and relapse. Existence of CSC’s in various types of tumours, including breast cancer
[50],[51] has been identified. ALDH (aldehyde dehydrogenase)-1 is a marker of normal and
malignant human mammary stem cells [52], and these cells can also be isolated using the cell
surface markers epithelial-specific antigen (ESA), CD44 and the absence of the expression of
CD24 [53]. When transformed cells undergo epithelial-mesenchymal transition (EMT), they
have been noted to gain properties of stem cells [54]. Although evidence supporting the CSC
model was initially obtained from acute myeloid leukemia [55], successive studies maintain
that solid tumors, including breast cancer tumors, are also driven and sustained by CSCs [50].
Regardless of origin, an abundance of research has clearly confirmed the existence of cancer
stem cells (CSCs) or tumor-initiating cells (TICs) in a variety of human cancers [55-58],
including breast cancer [50]. Nonetheless, most of the therapeutic approaches available,
inclusive of chemotherapy and radiation, lack the ability to effectively kill these populations
[59-62]. This may explain the lack of progress in eliminating cancerous tumors and preventing
metastasis and may help to rationalize therapeutic resistance; therefore, the CSC or TIC
population has become a target for cancer prevention and therapy [63]. A general consensus
exists in the literature that breast cancer re-occurrence is assumed to be caused by a sub-
population of tumor initiating cells possessing stem cell attributes of a tumor as well as
resistance to chemotherapy, radiation and other forms of treatment [64-66]. Of great interest
is the role of CSC’s in tumor relapse and resistance to therapy and recent articles suggesting
that such resistance can be overcome.
4. Breast cancer progression models
The combined research efforts of various scientific disciplines have resulted in the develop‐
ment of a disease progression model for breast cancer (See Figure 1) and include a continuum
of lesions through to invasive carcinoma and eventually metastatic disease [30, 48, 67, 68]. For
decades, it was thought that metastatic dissemination occurred as a final step in cancer and
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was the responsibility of genetic changes of malignant cells in the primary tumor [69]. In 2008,
Husemann et al, used transgenic mice to show systemic dissemination (specifically to lungs
and bone marrow) of mammary tissue derived premalignant cells prior to the emergence of
mammary tumors [70]. Additionally, this research reported that systemic dissemination of
tumor cells can occur in pre-invasive stages of tumor progression as observed in female
patients with ductal carcinoma in situ. A complementary accumulation of evidence supports
the evolution of an early dissemination model, where malignant cells outside the primary
lesion can also migrate to distal sites (such as lung and bone marrow) and cause tumors via
various genetic programs [54, 71, 72]. Such a model is inclusive to “self-seeding”, the term
coined when cancer cells not only seeds regional (lymph nodes) and distant sites but also fuel
the growth of the original tumor itself [73].
Figure 1. (Tobin, GA, 2011) Physiological Aspects of Disease Progression in Breast Cancer: The development of
breast cancer has been proposed as a multi-step process. The most deadly aspect of breast cancer is metastasis and
involves a cascade of reactions. Although the molecular mechanisms underlying this process are not fully understood,
any disruption along the cascade could arrest disease progression.
Thus, breast cancer is not a single disease, but rather an assortment of diseases with diverse
characteristics and clinical outcomes which will likely always require a variety and/or
combination of treatments or alternatively, a broad spectrum application. Combine this with
the fact that, despite major advances in our understanding of the biology of cancer, further
research is required to improve our understanding of tumor establishment, progression and
dissemination - the principal cause of mortality. Then, our goal in breast cancer research
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regarding treatment would be to identify novel therapies and maximize, based on our current
understanding of the disease, the use of such in preventing and treating as many aspects of
the disease as possible.
5. Molecular and endocrine controls
5.1. BRCA and other gene expression signatures associated with increased risk of breast
cancer
Less time, low cost and new sequencing technologies are all accomplishments that yield impact
on molecular biomedical research. Recently, for example, such advances (combined with some
prospective epidemiology studies) have allowed researchers to compare the DNA from
healthy breast tissue, initial tumor cells and then cells obtained nine years later when the breast
cancer had metastasized [74]. The 32 DNA mutations reported in the metastasized cells are a
prime example of how technological advances can serve to provide us with ample data
regarding gene expression that may offer insights into the progression of breast cancer disease.
However, consider that gene expression profiling / signatures of primary breast tumors can
only be used as a predictor of susceptibility or disease progression in breast cancer, particularly
metastasis. Currently, it is not possible to accurately predict the risk of metastasis or prevent
it. As a result, more than ½ of the patients treated with adjuvant chemotherapy are needlessly
exposed to harmful side effects [5]. This presents another compelling reason to further study
drug targets that are specific to, and have potential for, treatment in metastatic breast cancer.
Nonetheless, based on current knowledge, and aside from the many identified factors that
could impact the risk of developing breast cancer (including personal and environmental),
genetic mutations in critical cancer genes (both tumor suppressor and oncogenes) have been
identified for their increased or associated risk with breast cancer [75]. Of the many that have
been reported throughout the history of cancer genetics, Table 2 below captures those that
stand out principally for their research and/or clinical significance in relation to breast cancer
and summarizes major function, encoded proteins and known disease associations or risk
factors. Such genetic aberrations are acquired over a person’s lifetime; or less commonly, are
inherited. While it is estimated that only 5% to 10% of breast cancers are hereditary, some gene
variations are associated with both hereditary and somatic mutations [75]. The tumor sup‐
pressor genes BRCA1 and BRCA2 are the major genes related to hereditary breast cancer [76],
and mutations in these and other BRCA genes in women are associated with a 60-80% risk of
developing breast cancer throughout their life span [77]. Other genes with inherited altera‐
tions, including CDH1, PTEN, TP53, CHEK 2, and ATM have been noted to increase or are
associated with the risk of developing breast cancer [78]. Most notably, the latter three have
presented the strongest evidence related to the risk of developing breast cancer [79]. Somatic
mutations mostly reference ERBB2/HER2(neu) in breast cancer, however TP53 genes and
others have been associated with some cases of breast cancer in this manner [80]. It is note‐
worthy that not all people who inherit mutations in these genes will develop cancer.
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Gene Major Function: Associated Proteins Risk Factor Ref.
BRCA1 (BReast
CAncer gene one)
Encodes breast cancer type 1 susceptibility
protein; responsible for DNA repair,
transcriptional regulation and cell cycle check
point control.
Strong evidence indicating a 60 –
80% risk of developing breast
cancer for people with mutations.
[81 - 86]
BRCA2 (BReast
CAncer gene two)
Encodes BRCA2 susceptibility protein involved
in the repair of chromosomal damage,
especially in the error-free repair of DNA double
strand breaks. As with BRCA1, indicates a high
degree of risk.
Reduced levels of the BRCA2
protein may cause Fanconi
anemia. Patients with such are
prone to several types of cancers,
including reproductive system
associated tumors.
[87] [88]
ATM (Ataxia
telangiectasia
mutation)
Encodes protein with a phosphatidylinositol 3-
kinase (PI3K)–like domain which plays a central
role in the complex processes that repair DNA
double-strand breaks. Also involved in
regulation of cell cycle progression and the
maintenance of genomic stability.
Confers susceptibility and linked to
an modest increase (up to 2 times)
of breast cancer.
[89-93]
p53 (TP53) (Tumor
Protein p53)
Encodes p53 protein and regulates cell cycle,
preventing tumor growth.
Causes Li-Fraumeni syndrome:
results in higher-than-average-risk
of breast cancer and several other
cancers.
[94-96]
CHEK2
(Checkpoint kinase
2)
Encodes a serine/threonine-protein kinase
which plays a critical role in DNA damage
signaling pathways. Phosphorylates and
regulates the functions of p53 and BRCA1.
Causes Li-Fraumeni syndrome. Can
double breast cancer risk.
[97-99]
PTEN (Phosphatase
and tensin
homolog)
Encodes phosphatase and tensin homolog
protein, namely phosphatidylinositol-3,4,5-
trisphosphate 3-phosphatase, which is involved
in the regulation of the cell cycle.
Causes Cowden syndrome which
presents a higher risk of both
benign and cancerous tumors in
the breast, digestive tract, thyroid,
uterus, and ovaries.
[100, 101]
CDH1 (Cadherin 1
Gene) or E-
cadherin
(epithelial
cadherin)
Encodes E-cadherin protein. Down-regulation
decreases the strength of cellular adhesion,
increases cellular motility; allowing cell invasion.
Increased risk of breast cancer,
particularly invasive lobular breast
cancer.
[102-104]
** ERBB2,
(HER2/neu), or
VEGF
Encodes a transmembrane receptor with
constitutive tyrosine-kinase activity.
Amplification occurs in 15-30% of
human breast cancers.
[34] [80]
** ERBB2 (erythroblastosis oncogene B), HER2/neu (Human Epidermal growth factor Receptor2, neu: derived from a
rodent (neu)ral tumor), VEGF (vascular endothelial growth factor).
Table 2. Familiar Genetic Mutations, Encoding Proteins and their Major Functions in Relation to the Associated and
Increased Risk of Developing Breast Cancer.
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Those listed in Table 2, as mentioned, represent familiar genes associated with breast cancer.
However, others genes that are applicable in breast cancer progression will be reviewed in
terms of their associated cell signaling pathways. Considering the profound implications that
the CSC theory has for cancer chemoprevention and therapy, combined with our interest in
plant based molecules, we will also examine gene function in the context of opportunities for
natural product compounds in CSC self-renewal.
5.2. Endocrine controls
Over the years, and more notably since the discovery of suitable breast cancer cell lines and
animal models, the symbiotic relationship between lab research and clinical investigations
have advanced our knowledge of endocrine action. Breast cancer is influenced and highly
regulated by several sex and growth hormones (including estrogens, androgens, progesterone,
prolactin and insulin-like growth factors) and each of the sub-types and gene expression
patterns of breast cancer are characterized by both unique and specific endocrine controls
[105]. Particularly, estrogens and progesterone have received the greatest attention likely
because of their involvement in normal and neoplastic mammary tissue and the scale of their
associated risk estimation for breast cancer. Research into the role of androgens has likely been
a consideration in breast cancer research as androgens are necessary precursors to all endog‐
enous estrogens. The role of prolactin in the pathogenesis of breast cancer remains unclear
given the scarcity of studies to date. Similarly, although well studied, the role of Insulin-like
growth factor (IGF) in breast cancer is inconsistent.
There are challenges in defining the role of progesterone in breast cancer and the role of
progesterone receptor (PR) action in breast cancer remains divisive. In breast cancer, proges‐
terone has biphasic effects (both proliferative and inhibitory) on breast cancer cell lines grown
in vitro [106, 107]. Depending upon cellular context and/or the presence of secondary agents,
there may be a role for progesterone as a priming agent with growth promoting activity [106].
While progesterone is found as a single hormone, the major endogenous estrogens in fe‐
males include estrone (E1), estradiol (E2), and estriol (E3) and are primarily produced dur‐
ing menopause, in non-pregnant and pregnant females, respectively [108]. A variety of
synthetic (xenoestrogens) and natural substances have been identified that also possess es‐
trogenic activity including those derived from plant products (phytoestrogens) and fungi
(mycoestrogens) [108]. The actions of estrogens are mediated by their respective receptors
binding to specific DNA sequences to activate the transcription of estrogen receptor (ER)-
regulated genes, including direct target genes [109]. Approximately 80% of breast cancers
demonstrate expression of PR and/or ER [110]. Once established, these breast cancers which
are classified as either hormone-sensitive or hormone-receptor-positive cancers are reliant
on hormones to grow. Thus, treatment includes the suppression of hormone production in
the body for these specific breast cancers. Therefore, this section will provide an overview of
estrogens, their past indications in the treatment of breast cancer and their potential role in
relation to naturally occurring dietary compounds.
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5.2.1. The role of estrogens and breast cancer
The link involving estrogen and breast cancer can be traced back to as early as 1896 when a
surgeon in England reported an improvement in condition in three young female breast cancer
patients after the removal of their ovaries [111]. Since estrogen had not yet been discovered,
the surgeon had unknowingly removed the source of estrogen that promotes the survival and
division of cancer cells [111]. Since that time, a lot of evidence has shown that interactions
between estrogens and their receptors influence the pathogenesis of breast cancer. Estrogen
promotes proliferative effects on cultured human breast cancer cells [112]. Estradiol affects
breast cancer risk by controlling the mitotic rate of breast epithelial cells and high levels of
estradiol in post-menopausal women are also known to increase the risk of breast cancer [113].
Estradiol has also been shown to increase breast cancer risk via its metabolite, catechol estrogen
4-hydroxyestradiol, causing direct DNA damage through the formation of free radicals [114].
Estradiol has also been shown to modulate breast cancer cell apoptosis [115]. ER is a major
determinant of the cellular response of estrogen and has been indicated in breast cancer
promotion [116, 117]. The binding of estrogen to the ER modulates the transcription of a series
of genes, including those coding for proliferation.
The close relationship between the etiology of breast cancer and exposure to estrogen warrants
examination of key variables that may affect estrogen homeostasis, in particular those
exhibiting anti-estrogen activity. Because of their impact on the primary and metastatic aspects
of disease, anti-hormonal drugs are the mainstay breast cancer treatment. The goal in treating
hormone receptor +ve breast cancers is to utilize drugs which suppress production of estrogen
in the body. Estrogens in naturally occurring dietary compounds such as soy are used as an
alternative to hormone therapy because of their anti-proliferative effects. This practice, in
breast cancer treatment, is widely known as hormonal therapy, or anti-estrogen therapy, but
is not representative of the term hormone replacement therapy [118].
6. In vitro and in vivo breast cancer models and their relevance to human
disease
In 2007, Vargo-Gogola and Rosen summarized appropriately, within their title, the challenge
of modelling breast cancer; “One size does not fit all”[31]. Considering the heterogeneity
nature of this disease, these researchers rather addressed the reasonable question of the most
powerful way to investigate breast cancer with respect to cell lines and animal models. We
agree with their conclusion that an integrated and multi-systems approach is the strongest
way to model this disease. Here, we briefly discuss the most commonly utilized in vivo and in
vitro models and their relevance in human breast cancer.
6.1. Mammary carcinoma cell lines
Our current knowledge of breast cancer is mainly based on in vivo and in vitro studies com‐
pleted with breast cancer cell (BCC) lines. The first BCC line, namely BT-20, was established
in 1958 [119] and since then the number of permanent lines sustained are relatively low despite
continuous research in breast cancer [120]. In fact, the number of commercially available BCC
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lines (ranging from 70 – 80 based on ATCC and similar commercial suppliers) represent mostly
cell lines that were established more than 25 years ago. It has been suggested that this ineffi‐
ciency in producing new and improved lines is likely due to technical difficulties in extracting
viable tumor cells from their neighboring stroma [120]. In the past, it has been estimated that
more than two-thirds of all scientific abstracts related to studies on mentioned BCC lines
include the MCF-7, T-47D, and MDA-MB-231 lines [120]. Although no single cell line is entirely
representative of human breast cancer, cell lines have been widely used. As a result, we have
a greater understanding of breast cancer biology. Additionally, these cell lines have advanced
the ability of pre-clinical models to predict pharmaceutical activity and therapeutic applica‐
tions for further study. Despite this, the use of cell lines for application in human disease is
limited. The single most significant question, considering the devastating effects or outcomes
of metastasis, is the issue of whether these cell lines are representative of metastatic conditions,
or contain tumor initiating subpopulations. There are studies to indicate distinctions between
tumor and non-tumor initiating populations at the cellular and molecular level [31, 121].
Research indicates that the two luminal subsets (A and B) evident in tumors are not apparent
in the cell lines, and the basal-like cell lines are actually representative of two distinctive
clusters (A and B) that are not apparent in analyses of primary tumors [16]. The differences in
cell culture may be due to the absence of stromal or physiological interactions and/or signaling
[122] [123]. However, there is evidence that cell lines may be derived from subpopulations of
tumor cells that are selected because they grow well. For example, it has been noted that
differences between the genome aberration patterns for the basal-like and luminal clusters in
the cell line system don’t match differences in these subtypes in primary tumors. Furthermore,
the highly invasive Basal B cells carry the distinctive phenotype associated with the subpo‐
pulation of tumorigenic stem cells identified in breast cancer [50, 124]. Also, one must consider
the issue of variants of the same cell lines and the phenotypic changes that can occur due to
environmental exposures, rate of passage and age of cells.
Perhaps the most highly debated topic regarding the use of breast cancer cell lines revolves
around the MDA-MB-435 cell line, and by extension MDA-MB-435S (ATCC® HTB-129™) and
derivatives. Spontaneously metastatic and originally designated as Basal B and being derived
from a breast carcinoma, the MDA-MB-435 cell line has subsequently been questioned because
of recent evidence indicating that it might originate from melanoma or may have been cross-
contaminated with the M14 melanoma cell line [125-130]. While some researchers continue to
use this cell line as a breast cancer mouse model [131] and conclude that this cell line is in fact
breast cancer cells [132], others insist that the MDA-MB-425 cell line is a melanoma cell line
and renders its use as improper in breast cancer studies [133]. Later in the chapter, we will
describe some research that has been conducted using MDA-MB435 cell lines and/or its
derivatives as breast cancer models in research involving natural, despite this controversy.
This may not be all bad news for natural product researchers. On the bright side, natural
product therapies indicated in the controversial cells line MDA-MB-435 and its derivatives
then point toward activity in melanoma as opposed to breast cancer.
Nonetheless, there is clearly a need for new cell lines that are representative of all the known
sub-types of breast cancer. Currently, researchers have the option of using a group (or panel)
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of subtype cell lines to increase power in their research, as proposed by Neve [2006] [129]. To
date, and based on our knowledge, there has been no evidence of a male breast cancer derived
cell line. With the incidence of male breast cancer rising [2], relevant models require further
development.
Cell lines are easy to culture, inexpensive in comparison to animal models, and provide an
unlimited source of homogenous material to work with. Comparisons between researcher and
studies are usually fairly consistent and reproducible. A limitation of cell cultures is their
inability to measure tumor-stromal cell interactions, however the growth of cell lines for
transplantation allows for such in vivo.
6.2. Animal models
Animal models have allowed researchers to gain much insight into the disease progression,
in particular metastasis. In addition to advancing the concept of metastasis [134, 135], our
knowledge of the biological function of genes and signaling pathways has progressed as a
result of the vast amount of information generated from animal models. Experimental systems
based on mouse models that are currently used to study breast cancer can be categorized as
tumor transplantation and genetically engineered mice (GEM) – often termed as transgenic.
Here we will focus on commonly utilized models within each of these categories and discuss
some of the advantages and limitations of each in relation to human breast cancer disease
relevance.
6.2.1. Transgenic or (GEM) models
Different GEM breast cancer models are useful for studying distinct signaling interactions and
for testing therapies that target pathways involved. Genomic deletion of tumor suppressor
genes or the transgenic insertion of oncogenes allow these mice to be a relevant tool to
investigate the spontaneous initiation of breast tumors in each step of metastasis [136]. Specific
to breast cancer, the expression of oncogenes in explicit breast regions are restricted via a
mammary gland specific promoter [136]. MMTV (mouse mammary tumor virus) or WAP
(Whey Acidic Protein) promoter control the expression of oncogenes (i.e: PyMT, ErbB2, Wnt1,
or Ras) in transgenic mice and initiate mammary gland tumors which lead to metastasis in
various organs [137]. The MMTV-PyMT transgenic mouse model represents hyperplasia,
adenoma, and early or late carcinoma as seen in human cancer stages. In breast cancer, this
model demonstrates short latency tumor development specific to the mammary gland with a
high incidence pulmonary metastasis [138]. The deletion of mammary epithelial cell-specific
tumor suppressor genes results in similar conditions observed in human cancer patients,
including spontaneous tumors, bone metastasis, loss of estrogen receptor (ER) expression, and
hormone-responsiveness [139, 140]. Crossing GEM mice with other transgenic mice has
allowed researchers to investigate the role of genes and signaling pathways in tumorigenesis
and metastasis. While tumor progression was delayed in MMTV-PyMT or MMTV-ErbB2/neu
mice crossed into an Akt or PTP1B-deleted genetic background [141, 142], increased metastasis
was observed in the MMTV-PyMT mouse in a CD44_/_ background; the later indicates the
importance of receptors and other secreted factors in epithelial–stromal interactions or overall
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tumor environment [139]. In this regard, much insight has been gained through the use of GEM
models to indicate the role of both innate and adaptive immune responses in the progression
of breast cancer. For example, pulmonary metastasis is notably diminished via the selective
loss of the interleukin (IL-) 4 cytokine in PyMT/IL-4_/_ mice through inhibition of IL-4
mediated EGFR signaling of mammary tumors [143]. The understanding of such interactions
are important if we consider that tumor-associated immune cells release numerous growth
factors, including cytokines, chemokines, and enzymes that promote tumor growth, angio‐
genesis, and metastasis, and thus are associated with poor prognosis [136]. Inducible GEM
mouse models (those capable of expression or repression of certain genes) have advanced
knowledge with respect to the association of multiple genetic mutations of oncogenes in
relation to tumor establishment and maintenance [144]. There are several drawbacks to
consider in the use of GEM models. There are inherent differences in mouse and human, for
example: BRCA1 and p53 are on the same chromosome in mice, but not in humans [136, 144].
Technical discrepancies, depending on methods used to generate the model and the interpre‐
tation of results can present varying outcomes. Also, temporal and spatial tumor development
and metastasis differ depending on the mouse strain used. For example the percentage of ER/
progesterone receptor (PR)+ve tumors in Wap-Cre/Trp53_/_ mice are high while MMTV-Cre/
Trp53_/_ mice report a low incidence of such [145]. The molecular profile of mammary tumors
from GEM models represent the subtypes of human breast cancers, including those included
in Table 1, however no single model to date is representative of all expression patterns and
characteristics of human cancer.
6.2.2. Tumor transplantation model
Syngeneic transplantation refers to the transfer of cancer cells from one mouse into another
with identical genetic background [146] and such models are used to establish organ specific
metastasis [147]. The 4T1 breast cancer tumor model (a syngeneic mouse model) is considered
excellent for testing experimental cell-based immunotherapy strategies and is comparable with
stage IV human breast cancer [148]. The injection of 4T1 cells, originally derived from a
spontaneous mouse mammary tumor are injected into the mammary fat pad of a syngeneic
animal and the rapid proliferation of cells forms tumors and eventually metastasizes to the
lungs, liver, bone and brain [146, 147, 149]. Furthermore, this model has been refined through
the development of 4T1 cell lines to employ varying degrees of metastasis that are location
specific and representative of distinct gene expression signatures [150]. Xenograft transplan‐
tation encompasses the use of human cancer cells into immuno-compromised mice via
intravenous, intraperitoneal or subcutaneous injection, orthptopically or ectopically [136,
151]. First discovered in 1962, nude mice have been commonly used for xenotransplantation
because they lack a thymus and are unable to mount most types of immune responses,
including rejection of allografts and xenografts [152]. Severe Combined Immunodeficiency
(SCID) mice present with impaired ability to make T or B lymphocytes and are used as model
organisms for research into transplantation strategies as they cannot reject tumors and
transplants [153]. In general, rodents with immunological defects are typically resistant to
growth of mammary carcinomas, and despite improvements these approaches have yielded
low percentage of successful breast tumor engraftment compared to other types of cancers
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[154]. Recent mouse models have contributed significantly to the understanding of breast
cancer, however further research into suitable animal models will be required to advance
development of new therapies for breast cancer. The growth and metastasis of human breast
cancer cell lines in vivo allows the measurement of gene function relative to disease progression
and has provided much insight into the use of investigational drugs intended interrupt or
interfere with tumor growth [155].
Table 3 provides an overview of the defining characteristics of established breast cancer cell
lines (mouse and human) commonly used in both in vitro and transplantation models.
Cell line Species ER Status PR Status Metastasis Location Ref.
4T1 Mouse + + Lymph node, blood, liver, lung, brain,
bone
[149]
BT-474 Human + + Bone [156]
FII3 Mouse + + Lung [157, 158]
MCF-7 Human + + Lymph node, lymphatic vessel [159, 160, 161]
MDA-MB-231 Human − − Lung, liver, brain and bone [162, 163]
MDA-MB-435 Human − − Lung [164]
MDA-MB-453 Human − − Bone [165]
SUM1315 Human − − Lung, bone [166, 167]
SUM149 Human − − Lung [167]
T47D Human + + Lymph node, lymphatic vessel [168]
Table 3. Breast Cancer Cell Lines for in vitro and transplantation models
It is unlikely that any one transplantation model will ever replicate the complexity of the whole
cancer process; however studies to date demonstrate that xenographs are relevant in human
breast cancer. Treatment with Herceptin was shown to improve the anti-tumor activity of
paclitaxel and doxorubicin against HER2/neu-overexpressing human breast cancer xenografts
leading to consecutive favorable clinical trials [169, 170]. Davis et al. [2004] reported the
effective inhibition of tumor growth and metastasis in an orthotopic xenograft model by the
use of combination therapy of paclitaxel and neutralizing antibodies targeting vascular
endothelial growth factor receptor 2 (VEGFR2] [171]. The results of this research likely led to
the development of bevacizumab, a humanized monoclonal antibody that targets vascular
endothelial growth factor A (VEGF-A) [172]. Although, bevacizumab was removed as a breast
cancer indication by the FDA [173], this is yet another example of how transplantation models
lead to further development in the clinic. While these are merely a few cases for breast cancer
and the use of xenograft studies, the information obtained from such has been translated into
successful clinical trials for a variety of cancers [174-178]. Furthermore, useful information has
been gained from transplantation models with respect to toxicity and in the identification of
predictive biomarkers.
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In spite of these successes, the xenograft model presents disadvantages in its ability to predict
clinical response to therapy. Most animal tumors do not accurately model clinical metastatic
disease. The use of immuno-compromised mice prevents an immune rejection response which
is fundamentally different from the human system where the immune response promotes
primary growth of tumor cells and their migration to secondary organs [136, 179]. Most
xenograph models do not metastasize at the common sites of human breast cancer (such as
lymph nodes, liver, bone and brain) as they prefer to colonize in the lungs [5]. However,
improved models that have been created to represent human breast cancer metastasis from a
primary orthotopic site to human bone, such as initially published in 2005 by Kuperwasser et
al [167]. Consider that some xenograph models which utilize subcutaneous injection of tumor
cells into the flank and mammary fat pad are not as representative of clinical disease as those
that use orthotopic transplantation of cells into the mammary gland. Inherent discrepancies
in the background of mice and humans should be considered, and this is of particular
importance in predicting side effects for cancer therapy targets [180]. Additionally, the area of
metastasis can change depending on the cells line utilized or methods of inoculation [167];
thus, there are considerable technical issues. One could overcome such restrictions by use of
clinical isolates. However the utility of primary xerographs is inefficient; access is limited,
results are restricted by sample size and thus, studies to date indicate only some degree of
success [181]. Current research with aims to generate partial human immune systems or intact
populations of human cells in mice systems may also overcome such limitations. We must
consider that despite all advances to date, animals do not represent a complete model of human
disease. For example, tumor relapse would be especially problematic to study as the usual life
span in the majority of mice does not exceed two years. Aside from these underlying basic
issues, there have been issues associated with the testing of natural products within these
models. Further clarity on the fundamental mechanisms of tumor progression and metastasis
and new drug targets will be unveiled as mouse models advance. Until then, we will continue
to rely on current disease models and choose such based on disease state and therapeutic
targets.
7. Breast cancer signaling pathways
Each of the identified breast cancer subtypes and gene expression patterns are dependent on
different oncogenic pathways [105, 182]. The maintenance and differentiation of normal breast
tissue is controlled by many signaling pathways and involves cytokines and chemokines,
growth factors, steroid hormones, integrins, adhesion molecules and their respective receptors
[183]. The regulation of such by single or combined components of the tumor microenviron‐
ment (such as fibroblasts, macrophages / lymphocytes, endothelial cells, vessels and proteins
of the extracellular matrix (ECM) and stroma) have been implicated in various ways in the
promotion, growth invasion and metastasis of breast cancer [184]. Cross talk or communication
between the cancer cells and the factors within the tumor environment, including secretion
factors from the tumor itself, can modify expression and signaling [184]. Of the several
pathways indicated to play a role in cancer and CSC self-renewal, Notch, Wnt/Beta(β)-catenin,
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and Hedgehog (Hh) have been identified in human mammary cancer [124, 185, 186]. Addi‐
tionally, evidence has mounted to strengthen the link between nuclear factor kappa-B (NF-
κB), stem cells and breast cancer as elegantly reviewed in a recent paper by Shostak and Chariot
(2011) [187].
7.1. Notch pathway
Four Notch proteins, namely Notch-1 to Notch-4, are expressed as transmembrane receptors
in a variety of stem/progenitor cells [188, 189]. The binding of specific surface-bound ligands
are responsible for triggering cleavage events at the Notch proteins by ADAM (A Disintegrin
and metalloproteinase domain-containing protein) protease family and γ-secretase [188-191]
causing the intracellular domain of Notch to be released and translocate to the nucleus. Once
in the nucleus, downstream target genes (including c-Myc, cyclin D1,p21, NF-κB) are activated
[190, 192-197]. Known for their ability to modulate the development of various organs and
control cell proliferation [198], the notch activated genes and pathways have been reported to
drive tumor control through the expansion of CSCs [198-202]. This associated role in self-
renewal function of malignant breast cancers CSCs [198], combined with the fact that Notch
inhibitors can kill breast cancer cells in vitro and in vivo, may partially explain why Notch
expression and activation has been associated with a poor prognosis in mammary carcinomas
[203-205]. In fact, research findings in breast cancer have presented compelling reasons to
target Notch as a therapeutic target in solid tumors. In addition to its ability to regulate survival
and proliferation in bulk cancer cells [205] and CSCs [206-209], notch plays a pro-angiogenic
role in tumor endothelial cells [210, 211]. Farnie et al reported that activated Notch-1, Notch-4,
and Notch target Her-1 expression in ductal carcinoma mammospheres in situ samples, but
not from normal breast tissue [206, 212, 213]. Inhibition of Notch with a gamma-secretase
inhibitor (GSI) or a neutralizing Notch-4 antibody has been reported to reduce the ability of
ductal carcinoma in situ-derived cells to form mammospheres [207, 214]. Such results suggest
that Notch inhibition may have significant therapeutic effects in primary lesions, may be able
to preferentially target breast CSCs (responsible for reoccurrence and metastatic disease) and
counteract angiogenesis [213]. Cross talk with the NF-κB pathway and Notch1 have been
reported in a variety of cell interactions [192, 215-219], including the stimulation of NF-κB
promoters[217] and the expression of several NF-κB subunits [192, 215-220].
7.2. Wnt/β-catenin pathway
The canonical (Wnt/β-catenin) pathway, including Wnt-1, -3A and -8 is likely the best charac‐
terized and traditionally defines Wnt signaling, however other pathways have been described
including a non-canonical (planar cell polarity) pathway (including Wnt-5A, - 11) and the Wnt/
Ca2+ pathway (protein kinase A pathway) [221-224]. Although it has been more than 25 years
since the discovery of the Wnt gene, its structure remains unknown and signaling pathways
are not well defined, especially those independent of β-catenin. Perhaps this challenge can be
somewhat explained by the recent discovery that differences in cell signaling outcomes may
be attributable to precise pairings of Wnt ligands with analogous cellular receptors [225]. For
example, if we consider that the mammalian genome codes for 19 Wnt proteins and 10 Fzd
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receptors, there are potentially 190 Wnt/Fzd pairing combinations [226]. Although all of these
ligand/receptor pairings have not been unveiled, we already know that the Wnt/β-catenin
pathway has been established for its ability to alter cell proliferation, migration, apoptosis,
differentiation and stem cell self-renewal [224, 227-230]. The essential mediator of the canonical
pathway is β-catenin, and its two known distinct functions are based on cell specific locations.
Accumulation of β-catenin within the cytoplasm leads to activation of Wnt target genes such
as c-Jun, c-Myc, fibronectin and cyclin D1 [186, 231-236]. Prior to nuclear translocation, β-
catenin operates in the membrane to maintain cell–cell adhesion via cooperation with the
epithelial cell–cell adhesion protein E-cadherin [223]. The Wnt signaling pathway is activated
via the binding of ligands to transmembrane receptors encoded by the Frizzled (Fzd) gene
family and in conjunction with co-receptors, such as low-density lipoprotein receptors (protein
5 and 6) [237] This Wnt-Fzd interaction results in dephosphorylation, accompanied by
decreased levels of degradation and causes the accumulation of β-catenin in the nucleus [231].
In the absence of Wnt signaling, β-catenin is quickly degraded in the cytoplasm. Without Wnt
signaling, phosphorylation of adenomatous polyposis coli (APC) [238] via a cytoplasmic
destruction complex results in ubiquitination of β-catenin which is then prone to proteasomal
degradation [231]. Additionally, nuclear levels of β-catenin are lessened by their interaction
with APC and Axin, both known for their function in transporting β-catenin back to the
cytoplasm. In the nucleus, transcriptional corepressors interact with DNA-binding T-cell
factor/lymphoid-enhancer factor (Tcf/Lef) proteins, such as Groucho/TLE, and are enabled to
block target-gene expression when β-catenin is held at low levels. [239-242]. Wnt binding to
the Fzd or low-density lipoprotein receptor protein-membrane receptors results in the
accumulation and stabilization of translocated (from cytoplasm to nucleus) β-catenin [237].
Inhibition of such interactions has been noted by secreted Fzd-related proteins, Dickkopfs, and
Wnt inhibitory factor-1 (WIF-1) [243, 244].
Since the initial observation that Wnt overexpression results in malignant transformation of
mouse mammary tissue [245], aberrant regulation of the Wnt signaling pathway has emerged
as a prevalent theme and continues to develop as a fundamental mechanism in broad cancer
biology [246]. While Wnt pathway mutations (genetic and epigenetic) are rare in mammary
carcinoma, overactive Wnt signaling has been noted in the majority of breast cancers, includ‐
ing rare classes (i.e.: triple -ve type) via several potential mechanisms [145, 233, 247-256]. Several
studies to date have indicated that the expression of both Wnt receptors and their ligands are
characteristic of breast cancer and furthermore certain receptors and ligands may be breast
cancer type specific. In 2004, Bafico et al. reported autocrine Wnt signaling in a panel of breast
cancer cell lines, including MDA-MΒ‐231, which were identified by the presence of unstabi‐
lized β‐catenin and then subsequently reduced upon expression or by the addition of the soluble
Wnt inhibitors sFRP1 or DKK1 [257]. The expression of the Wnt receptor FZD7 is characteris‐
tic of certain rare types of breast cancer [258]. Additionally, the knockdown of FZD7 in cell lines
representative of triple -ve breast cancer reduced the expression of Wnt target genes, inhibit‐
ed tumorigenesis in vitro and greatly retarded the capacity of the MDA-MD-231 cell line to form
tumors in mice [246, 259]. With respect to Wnt ligands, secreted frizzled related protein (sFRP)-1,
an effective competitor and binding site with FZD receptors for Wnt ligands, has been shown
to be ectopically expressed in the MDA-MΒ‐231 cell line [260]. This same study showed that the
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sFRP1 expressing cells struggled to form tumors upon inoculation into the mammary fat pads
of mice and their propensity to metastasize to lung was greatly impaired [260].
Specific to the maintenance of CSCs, Wnt/β-catenin signaling is implicated in many cancers
[223, 224, 261-268], including breast cancer [269]. For example, radiation resistance of mouse
mammary stem/progenitor cells has been correlated with overexpression of β-catenin in the
stem cell survival pathway [266]. Additionally, overexpression of Wnt/β-catenin signaling was
reported to promote expansion of the hepatic progenitor cell population in animal studies
[267] and the elimination of β-catenin abrogates chemoresistant cell populations endowed with
progenitor-like features [57]. Of great interest is the link between Wnt/β-catenin and PI3K
(phosphoinositide 3 kinase) /Akt (protein kinase B) pathway as established by several studies.
Korkaya et al. demonstrated that PI3K/Akt pathway is important in regulating the mammary
stem/progenitor cells by promoting β-catenin downstream events through phosphorylation
of GSK3β [60, 189]. Other studies have revealed the ability of activated Akt, such as phospho-
Akt Ser473 to phosphorylate Ser9 on GSK3β, thereby decreasing the activity of GSK3β, and
potentially stabilizing β-catenin [270-272].
In summary, the proof of concept for inhibiting Wnt signaling in cancer is in place. Furthermore
there is an increasing amount of evidence to support a role for Wnt signaling in breast cancer;
thus, a target has been created for future studies. Specific to breast cancer, the emphasis on
target development ranges from antagonizing Wnt ligand secretion or binding to promote β-
catenin degradation to specifically blocking β-catenin-mediated transcriptional activity [222].
Nonetheless, as noted several times throughout this chapter, the cooperation of Wnt pathway
with other signaling pathways in cancer is an important consideration. Aside from the
challenge of determining the most efficacious way to inhibit Wnt related factors, possible safety
concerns should be considered; another compelling reason to explore specific targets in the
Wnt pathways for all breast cancer sub-types.
7.3. Hh pathway
A crucial mediator of normal tissue development, with recent indications as a regulator of
tumor-related vascular formation and function [273], the Hh signaling pathway in cancer is
activated by ligand independent mutations in the pathway or through Hh overexpression
(ligand-dependent) [189, 274, 275]. In the absence of Hh ligands, (Sonic Hh, Desert Hh and
Indian Hh), their transmembrane receptor Patched (Ptch) associates with and blocks the G-
protein-coupled phosphoprotein receptor Smoothened (Smo) and is only released when
secreted Hh ligands bind to Ptch [189, 276, 277]. This binding triggers the dissociation of
glioma-associated (Gli) family of zinc finger transcription factors. The three Gli proteins found
in vertebrates include Gli1 and Gli2 (thought to activate Hh target genes) and Gli3 (known to
act primarily as a repressor) which lead to the transcription of an assortment of genes including
cyclin D, cyclin E, myc and elements of EGF pathway effectors through complex interactions
with Costal2 (Cos2), Fused (Fu) and Suppressor of Fu (SuFu) [276-278]. Somatic mutations
which activate Hh pathway have been implicated in a variety of human malignancies[278]
including basal cell carcinomas, pancreatic cancer, medulloblastomas, leukemia, gastrointes‐
tinal, lung, ovarian, breast and prostate cancers [274, 275, 279]. Both in vitro and mouse model
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systems have demonstrated that the Hh signaling pathway plays a crucial role in regulating
self-renewal of normal and malignant human mammary stem cells [51, 189]. Hh pathway
inhibition has been shown to result in tumor growth inhibition mediated through the stromal
microenvironment; as demonstrated in a xenograft model using a tumor and stromal cell co-
injection procedure, and consistent with a paracrine signaling mechanism [280]. Although data
describing the genetic alteration and the modulation of the expression pattern of Hh pathway
components in mammary gland are limited, possible indications for the Hh pathway in
development and maintenance of mammary cancer have been proposed [281]. However, a
more significant role of Hh signaling has been revealed in prostate cancer studies, demon‐
strating that autocrine Hh signaling by tumor cells is a requirement for proliferation, viability
and invasive behavior [282]. Additionally, the association of accelerated prostate cancer
growth and progression with increased Hh signaling has been reported [283]. The Hh signaling
pathway has been demonstrated as a critical pathway involved in stem cell self-renewal [276]
including the essential role of Hh-Gli signaling in controlling the self-renewal behavior of
human glioma CSCs and tumorigenicity [189, 284]. Known for its central role in the control of
proliferation and differentiation of both embryonic stem cells and adult stem cells, aberrant
activation of Hh signaling could be involved in the generation of CSCs and the development
of cancer [278, 285]. In this regard, the development of Hh inhibitors may be a solution in the
treatment of human cancers, including prevention of tumor progression. Essential similarities
have been noted between Wnt and Hh signaling pathways [286] and their key roles in the
physiological and pathological development of both embryonic and stem cells [278] [278]gives
rise to the fact that crosstalk exists between the two. Signaling for both are activated by G-
protein-coupled receptors [287, 288] and prevents phosphorylation-dependent proteolysis of
key effectors (Cubitus interruptus or β-catenin) responsible for the conversion of a DNA-binding
protein from a repressor to an activator of transcription [278, 289]. Considering the progression
model of many cancers, specifically metastasis to bone, it is interesting to note that Wnt
signaling has been reported to be downstream of Hh signaling, participating in bone devel‐
opment [278, 290]. Further proof proposing that Wnt signaling is downstream of Hh includes
the ability of activated Gli1 to stimulate the transcription of Wnt ligands [276, 278]. It has been
noted that molecules involved in Wnt signaling (i.e: GSK-3β) also play a regulatory role in Hh
signaling [278, 286]. Furthermore, canonical Wnt/β-catenin signaling is required for the
pathological response to oncogenic Hh signaling [278, 291].
7.4. NFĸB Pathway
Along with their hallmark roles in cell survival, proliferation, inflammation and immunity,
the NF-κB family of transcription factors are often constitutively expressed in breast cancer
tumors [292]. Early studies on NF-κB pathway determined its key role in mammary epithelial
proliferation, architecture and branching during early post-natal development [293, 294].
However, independent of its effects on mammary development, evidence exists to suggest that
NF-κB regulates breast tumor progression [293, 294]. Constitutive activation of NF-κB in
several breast tumor cell lines has been shown to profoundly affect the initiation and progres‐
sion of breast cancer [295]. NF-κB is also required for the induction and maintenance of the
EMT a process that critically controls breast cancer progression [296, 297]. Additionally, it is
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evident that NF-κB mostly acts in specific breast cancer sub-types, namely estrogen receptor
(ER)-ve and ErbB2+ve tumors [298, 299] and has been implicated in stem cell expansion in
breast cancer studies [187].
Activation of NF-κB results in the constant nuclear localization of proteins including p50, p52,
p65, cRel and RelB which subsequently up-regulate anti-apoptotic proteins causing an
imbalance between normal cell growth and apoptotic cell death [300]. NF-κB-activation occurs
mainly through two well characterized pathways, namely the canonical (classical) and the non-
canonical (alternative). Both pathways systematically work in a similar fashion in that they are
reliant on signal-induced phosphorylation and degradation of an inhibitory molecule to
release and transport nuclear NF-κB proteins. However, they differ in the types of trigger
signals, activated kinases, inhibitory molecules and NF-κB proteins utilized in each system. In
addition to each of these aforementioned pathways, other NF-κB activating pathways exist
and have been indicated in the initiation and progression of breast cancer, however we will
not discuss these fully in this chapter other than in the context that they appear in the described
and relevant research experiments.
Specifically, the canonical pathway involves translocation of a p50/p65 heterodimer to prompt
the expression of genes intricated in cell proliferation as well as their survival, inflammatory
properties and role in innate immunity [292]. This process occurs through a transforming
growth factor beta activated kinase-1 (TAK1)-dependent pathway and is normally dependent
on members of pro-inflammatory cytokines such as tumor necrosis factor-alpha (TNFα) or
IL-1β and other pro-inflammatory cytokines to degrade the inhibitor (IκBα) by the NF-κB
essential modulator ((NEMO)/IκB kinase (IKK))γ-containing IKK complex [292]. In 2004,
Biswas et al. published results regarding the activation of NF-κB in human breast tumors and
in carcinoma cell lines indicating that the canonical pathway contributes to tumor development
[298]. The resulting highlight of this experiment gave rise to activated NF-κB as a therapeutic
target for distinctive subclasses of ER-ve breast cancers [298]. Specifically, the (NEMO)-binding
domain (NBD) peptide (a selective inhibitor of IKK) blocked heregulin-mediated activation of
NF-κB and cell proliferation while inducing apoptosis on proliferating cells substantiating the
hypothesis that certain breast cancer cells rely on NF-κB for aberrant cell proliferation and
simultaneously avoid apoptosis [298]. More recently, Connelly et al. [2011] showed, via genetic
approaches, that the canonical NF-κB-activating pathway is inhibited in defined frames during
polyoma middle T oncogene (PyVT) tumorigenesis and that interruption of this pathway in
the mammary epithelium increases the latency of tumors and decreases tumor burden [301].
The non-canonical pathway, considered to be critical in adaptive immunity, is similar to the
canonical cascade as it also relies on an IKKα heterodimer, but not on NEMO/IKKγ [302]. Prior
to nuclear shuttling of 52/RelB dimers, the inhibitory molecule p100 is partially degraded
through an NF-κB-inducing kinase (NIK)-dependent pathway [292]. Early studies revealed
the enhanced expression of the NF-κB protein p52 in breast cancer samples giving rise to the
involvement of the non-canonical pathway [303],[304]. The NF-κB protein RelB is increased in
ERα-ve breast cancer cells and is required for the maintenance of mesenchymal ERα-ve breast
cancer cells partially through the transcriptional induction of BCL2 [305]. Furthermore, RelB/
p52 complexes have since been implicated in mammary carcinogenesis. For example, mouse
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mammary tumors induced by 7,12-dimethylbenz(a)anthracene treatment have been shown to
increase RelB/p52 activity and the inhibition of RelB in breast cancer cells repressed cyclin D1
and c-Myc levels and growth in soft agar [306]. Perhaps the most conclusive proof of non-
canonical NF-κB-activating pathway involvement occurred in studies employing a novel
transgenic mouse model to consider the role of involved mediators (downstream of p100/p52]
in both mammary development and tumorigenesis [307]. The results of this study indicated
an increase in p100/p52 expression in tumors from mice expressing PyVT in the mammary
gland, [307] with no change of nuclear p65 detected; an indication that the observation was
limited to a deregulated non-canonical NF-κB-activating pathway [307].
7.4.1. NF-κB and breast cancer stem cell renewal
Recently, studies have strengthened the association between stem cells, breast cancer and NF-
κB. Such have been captured in a review by Shostak and Chariot highlighting experiments to
date complemented by a compelling rationale for targeting NF-κB and other developmental
pathways involved in the self-renewal of normal stem cells [187]. The involvement of NF-κB
in various signaling cascades has proven critical in several studies involving breast cancer stem
cell expansion.
Cao et al. [2007] showed that IKKα is both a regulator of mammary epithelial proliferation and
a contributor to ErbB2-induced oncogenesis [308]. Specifically, breast cancer cells from IKKα
(AA/AA) knock-in mice (whereby IKKα activation is disrupted) crossed with the Her2 murine
breast cancer model, exhibited diminished self-renewal capacity and resulted in the inability
to establish secondary tumors [308]. Breast cancers that generate primary, as opposed to
secondary mammospheres such as seen in mice used in these experiments, suggests that
IKKα is likewise required for the self-renewal of tumor-initiating cells from the Her2 breast
cancer model [187]. Additionally, mutated IKKα slowed tumor development following
exposure to 7,12-dimethylbenzaanthracene or the MMTV-c-neu (ErbB2/Her2) transgene;
however there was no effect on MMTV-v-Ha-ras-induced cancer despite the fact that both of
these oncogenes rely on cyclin D1 [308]. In this same series of studies, carcinoma cells from
another mouse model (IKKα(AA/AA)/MMTV-c-neu) underwent premature senescence when
cultured under conditions used for propagation of mammary gland stem cells. Altogether,
these mouse models of breast cancer show that IKKα seems to act as a central protein in the
activation of NF-κB during breast cancer stem cell self-renewal [308]. Therefore, the researchers
concluded that IKKα may represent a novel and specific target for treatment of ErbB2+ve breast
cancer.
While NF-κB appears to be activated in luminal progenitor cells during differentiation of
mammary colony-forming cells [309], the mammary stem-like basally located cells are devoid
of NF-κB activity [309, 310]. Taken together, these studies suggest that only the canonical NF-
κB pathway is active in normal luminal progenitor cells before transformation and is re‐
quired for the formation of mammary luminal-type epithelial neoplasias [309]; a reminder of
the importance of understanding the cellular etiology underpinning breast tumor heterogene‐
ity [310].
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Another interesting role for NF-κB signaling involves the link between inflammation and
cancer. While the mechanism linking inflammation and cancer has yet to be explained, we do
know that the inflammatory cytokine, interleukin(IL)-6 is up-regulated in epithelial cancers,
including breast cancer [311]. We also know that NF-κB regulates the expression of anti-
apoptotic genes and activates different pro-inflammatory cytokines and chemokines, includ‐
ing IL-6 [312, 313]. Further clarity on the interactions of NF-κB signaling, inflammation and
cancer has been gained through a study showing that the temporary activation of Src onco‐
protein mediates an epigenetic event whereby immortalized breast cells are stably transformed
to a cell lines that represent self-renewing mammospheres containing cancer stem cells [313].
The inflammatory response triggered by the activation of Src and further downstream
signaling which inhibits IL-6 expression is mediated by NF-κB [313]. It has been shown that
the transformation of cells utilized within this experiment occurs via a positive feedback loop
whereby IL-6 mediated STAT3 transcription factor stimulation activates NF-κB [313]. These
authors have demonstrated that Src activation triggers a rapid inflammatory response
mediated by NF-κB that is critical for cellular transformation. While this study defines Src’s
role as an oncogenic kinase promoting the expansion of breast cancer stem cells, it also
demonstrated the critical involvement of NF-κB in the process [313].
It is known that the onset of progestin-driven breast cancer is affected by the deletion of
IKKα in mammary-gland epithelial cells [314]. Such studies are relevant in breast cancers as
they consider the importance of associated risk factors between hormone replacement therapy
(i.e.: progesterones or synthetic derivatives) and the increased risk of incident of fatal breast
cancer [314]. The expression of both receptor activator of NF-κB (RANK) and RANK ligand
(RANKL) have been observed in primary breast cancers in humans and breast cancer cell lines
[315]. Studies to date indicate that the RANKL/ RANK system is mediated in part by IKK-α–
NF-κB signaling and controls the incidence and onset of progestin-driven breast cancer; more
specifically a loss of RANK expression significantly impairs the self-renewal capacity of cancer
stem cells [314, 316]. Thus, because of the link between the RANKL/RANK system and
progestin-driven epithelial carcinogenesis, RANKL inhibition could be considered as a novel
approach to the prevention and/or treatment of breast cancer [314].
More recently, a model of Her2-dependent tumorigenesis indicated that breast cancer stem
cell renewal is regulated by epithelial NF-κB through a reduction in the expression of key
embryonic stem cell regulators, namely Sox2 and Nanog [317]. Specifically, NF-κB was
required for both proliferation and colony formation of Her2-derived murine mammary tumor
cell lines [317]. Additionally, the rate of initiation of Her2 tumors was governed by NF-κB [317].
7.5. Summarizing pathway interruptions/targets
In many human breast cancers, all three developmental pathways (Wnt, Notch and Hh) appear
to be deregulated and control the self-renewal of normal stem cells from a molecular perspec‐
tive [186]. Additionally, the involvement of NF-κB has emerged as another involved pathway
in breast cancer based on what we know about Her2, a membrane bound receptor tyrosine
kinase. Her 2 is overexpressed in 30% of breast cancers and critically controls the cancer stem-
cell population [318]. Since Her2 activates NF-κB through the canonical pathway [319] [27],
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the hypothesis exists that the NF-κB pathway may be involved in the biology of breast cancer
stem cells. It is also obvious that these interrupted pathways, and likely others unknown at
this time, are responsible for certain stages of cancer progression or cancer cell aggression. If
so, then we are in agreement with others who have noted that the development and identifi‐
cation of selective inhibitors of specific signaling pathways is an attractive approach for the
prevention of tumor progression and/or treatment of cancers [278]. However, we have also
mentioned several examples of cross-talk between the components of different cell signaling
pathways. This concept then introduces the task of targeting multiple pathways in an effort to
prevent progression and metastasis of cancers. Alternatively, and based on the premise that
certain pathways operate downstream of others, it would be more reasonable to focus on
inhibitors of overarching pathways, such as NF-κB. In summary, such oncogenic pathway
signatures are fundamental in natural product testing. Therapeutic approaches involving
natural products may provide a link between pathway deregulation and therapeutic sensitiv‐
ity indicating an opportunity for the development of target compound(s).
8. Prevention and treatment of breast cancer with natural products: Past
successes and promising future treatments
Currently, hormones and cytotoxic drugs remain the standard treatment for metastatic breast
cancers. Development of a therapeutic approach for treating tumors, tumor reoccurrence and
metastatic tumors is crucial for reducing mortality in cancer patients [6]. There is an urgent
need to explore agents that will be effective in preventing and treating metastasis of breast
cancer. For centuries, nature has provided us with a rich source of compounds for various
disease treatments. Such naturally-derived molecules have been utilized in formal drug
discovery platforms of the pharmaceutical industry. Greater than 60% of new chemical entries
at the National Cancer Institute from 1981-2002 were either natural products or were derived
from natural products [320]. Such naturally-occurring sources can be defined by their origin
and include biotic (i.e.: forests, plants, animals, birds and marine organisms) and abiotic (i.e.:
land, water, air and minerals such as gold, iron, copper, and silver) components [321]. Within
these categories, plants have proven to be a rich source of lead compounds (i.e: alkaloids,
morphine, cocaine) or the basis for synthetic drugs (i.e: anesthetics from cocaine) [320, 321].
The complexity and variation of plant structures indicates that their evolution has naturally
completed the screening process and that the creation of potent compounds makes them more
likely to survive. Plants offer the advantage of abundance, and even with such clinical
successes as paclitaxel (Taxol) from the yew tree, and the antimalarial agent artemisinin from
Artemisia annua, the vast majority have not been studied [320]. Due to promising bioactivity
and diversity, the plant environment offers a potential source of natural products. A vast
number of studies in the discipline of epidemiology have confirmed an association between
fruit and vegetable consumption and the reduced risk of several cancers resulting in an
increased interest in the role of naturally occurring dietary compounds in the efficacy of cancer
chemoprevention [322]. Thus, the exploration of plant-based molecules as anti-cancer drugs
is appropriate.
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The history of Tamoxifen and its derivatives in the successful treatment of estrogen receptor
(ER)+ve breast cancers are well documented. In the past Tamoxifen was successful in reducing
breast cancer mortality rate in hormone receptor+ve breast cancer patients by up to a third and
thus was the stronghold of endocrine treatment [323]. Clinical trials have indicated that
aromatase inhibitors (AI) have improved efficacy compared with Tamoxifen for the treatment
of post-menopausal hormone receptor+ve patients [324-327]. Additionally, the response rate
for third generation AIs as first-line agents range from 30%–50% in ER+ve advanced breast
cancer. [323]. Leading to these discoveries, and in an effort to capitalize on the advantages of
both anti-aromatase and anti-estrogenic activity, many natural products have been tested for
their ability to prevent and treat breast cancer, in vivo and in vitro. Table 4 summarizes plant
based compounds that have been indicated for their potential as a prevention or treatment in
breast cancer. This list is not exhaustive; however it does capture the extracts studied to date
according to activity in cell lines and animal models and represents the most common types
of breast cancer. In addition to those listed within Table 4, soy-based extracts, curcumin and
piperine have been studied and we will discuss these in detail as the most promising plant
based targets in the prevention, treatment and progression of breast cancer.
9. Promising plant based targets in the prevention, treatment and
progression of breast cancer
9.1. Summarizing the individual and combined effects of the soy isoflavones, genistein and
diadzein, on mammary tumor development, metastases and invasive breast cancer cells in
vivo and in vitro
Genistein, daidzein and glycitein are the main isoflavones present in soybean and soy-based
foods [341] [342]. Out of these, genistein is the mostly studied and dominant isoflavone of soy
against breast cancer and has progressed to phase II clinical trials [343]. Soy isoflavones acting
upon breast cancer cells in vitro and in vivo have been studied extensively with varying results
and the clinical implications specific to breast cancer have been discussed. Soy isoflavones are
structurally similar to female androgen estrogen, and thus they are also known as phytoes‐
trogens [344] and may possibly be competing with the physiological estrogens. Genistein and
daidazine (but not glycietein) possesses the ability to transactivate the estrogen receptors.
Utilizing cell based assays on MCF-7 human breast cancer cells, estrogenic agonist actions of
soy isoflavones have been studied by Matsumura and co-workers whereby genistein and
daidzein exert estrogen response in MCF-7 cells [345] via ER with higher affinity to ERβ1.
Similarly, in hepatoma cells transfected with ER, genistein and daidazine bind to both ERα and
ERβ but with more affinity to ERβ. Genistein is more potent compared to daidazine [346].
However, these phytoestrogens are 400-600 times less potent compared to 17-β estradiol [347].
In vitro, genestein is capable of identifying cells that specifically carry BRCA1 mutation and
strongly inhibits the growth of BRCA1 mutant cells compared to cells expressing the wild-type
BRCA1 protein [348]. The resistance shown by cells expressing wild type BRCA1 protein has
been attributed to increased AKT and decreased p21 (WFA1/CIP1) protein levels [349].
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Natural Product; Active
Ingredient
Effect Ref.
White button mushrooms
(Agaricus bisporous);
Conjugated linoleic acid and its
derivatives
Decreased both tumor cell proliferation and tumor weight with no
effect on rate of apoptosis in MCF-7aro cells and nude mice injected
with MCF-7aro cells.
[324]
Taxus brevifolia (Pacific Yew)
and other Taxus derivatives;
Paclitaxel
Promotes tubulin polymerization and stabilization of microtubules
against depolymerization.
[328] [329]
Dysoxylum binectariferum;
Flavopiridol
Inhibition of MMP-2 and MMP-9 secretion of in MDA-MB-435
(parental) and 435.eB (stable transfectants) breast cancer cells.
[330]
Green Tea;
Epigallocatechin gallate
Suppresses receptor (ERα) MBA-MB-231 breast cancer cell growth in
vitro and in vivo in combination with curcumin.
[331]
Bloodroot
(Sanguinaria Canadensis);
Sanguinarine
Induced apoptosis through mediation of ROS production in MDA-
MB-231 breast carcinoma cells, decrease in mitochondrial membrane
potential,
release of cytochrome c, activation of casp-3, and casp-9 and down
regulation of Bcl-2.
[332]
Garcinia hanburyi.
(Gamboge tree);
Gambogic acid
Upregulation of p53 and down regulation of Bcl-2 resulting in
apoptosis in MCF-7 cancer cells.
[333]
Ganoderma lucidum;
Ganoderic acids
Inhibits AP-1 and NF-ĸB activity; inhibition of u-PA secretion from MDA-
MB-231 cells.
[334]
Ginger;
Acetoxychavicolacetate
Decreased cell viability in MCF-7 and MDA-MB-231 cells via casp-3-
dependent increase in apoptosis.
[335]
Grapes, fruits, and root extracts
of the weed
Polygonum cuspidatum);
Resveratrol
Suppresses NF-ĸB activation and cell proliferation in MCF-7 cells,
reduced expression of Cox-2 and MMP-9 (with a reduced NF-ĸB
activation).
[336]
Garcinia indica (kokum);
Garcinol
Induced apoptosis in MCF-7 and MDA-MB-231 cells via caspase
activation and down-regulation of NF-ĸB regulated genes.
[337]
Plumbago europaea
(Plumbago); Plumbagin
Induced apoptosis with concomitant inactivation of Bcl-2 and the DNA
binding activity of NF-ĸB in MCF-7aro breast cancer cells.
[338]
Rotenone; Deguelin Arrests cells at the S phase resulting in anti-proliferative effect in MDA-
MB-231 cancer cells.
[339]
Silymarin; Silibinin Reduced PMA-induced invasion of MCF-7 cells through specific
inhibition of AP-1-dependent MMP-9 expression.
[340]
Table 4. Plant Based Natural Products indicated in Breast Cancer
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Cyclooxygenase-2 (COX-2) expression, which is associated breast cancer risk [350], can also be
inhibited by soy isoflavones [351]. Thus, it seems that soy isoflavones are capable of curtailing
breast cancer risk factors.
The influences of soy isoflavones on cell growth, cell cycle and apoptosis are all relevant to
their effectiveness as chemopreventive agents for breast cancer. A number of studies have
indicated the potential of genistein to inhibit proliferation of breast cancer cells in culture by
causing cell cycle arrest and/or apoptosis. Genistein induces G2/M cell cycle arrest [352-354].
This effect was seen both in hormone sensitive and hormone independent cells [352]. Accord‐
ing to Li et al. [2008] G2/M cell cycle arrest occurs, via stable activation of ERK1/2 pathway [354].
Demarcation on the relative importance of cell adhesion, invasion and migration for primary
tumor growth verses metastatic tumour growth is not clear. However, motility, migration and
adhesion are more connected to metastasis which is undoubtedly the most life-threatening
aspect of breast cancer. Thus, it is crucial to identify the effects of soy isoflavones on disease
metastasis.
Microarray analysis of genistein treated HCC1395 cells, a cell line derived from an early stage
primary breast cancer, has indicated up-regulation of genes that inhibit invasion and down-
regulation of genes that promote invasion [355]. Genistein enhances the adhesion of breast
cancer cells [356, 357]. This may possibly be one method utilized by genistein to reduce
metastasis.
A study by Vantyghem et al (2005) describes the ability of dietary genistein to affect metastasis
in a post–surgical model in mice [358]. This test model mimics the clinical situation where
primary tumors are surgically removed and therapeutic strategies are applied to prevent the
growth of any cancer cells seeded to other locations prior to surgery. In this study, primary
tumours were established by injecting human breast carcinoma cells, MDA-MB-435/HAL, into
the mammary fat pad of nude mice. After 5 weeks, tumours were surgically removed and mice
were maintained with a soy free diet or genistein supplemented diet. At the end of 5 weeks, a
10 fold reduction in percent lung metastasis in mice fed on a genistein supplemented diet was
seen. In another study, as described by Zhang et al., genistein has shown its ability to reduce
the number and volume of osteolytic bone metastases in Balb/c(nu/nu) mice injected with
MDA-MB-231 human breast cancer cells [359]. As there are clear indications of the ability of
this compound to inhibit breast cancer metastasis, as described in the various animal studies,
it would be useful to identify the associated molecular mechanisms. Although there are no
conclusive findings, a number of different mechanisms have been suggested.
In studies focused on determining related mechanisms, scientists have given more attention
to molecules that are overtly expressed in malignant breast tumours. For example, much
attention has been invested into the actions of focal adhesion kinase (FAK), a tyrosine protein
kinase. As described previously, cell motility is an integral part of metastasis and it is justifiable
to investigate the components directly involve in cell motility. FAK has been designated as a
regulator of cell migration and invasion [360]. Since over expression of FAK in human tumors
occurs, it has been proposed as a potential therapeutic target [361]. Increased expression of
FAK expression in invasive breast carcinomas is associated with an aggressive phenotype
[362]. In a transgenic model of breast cancer, mammary epithelial specific disruption of FAK
blocks transition of premalignant hyperplasias to carcinomas (and their subsequent metasta‐
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sis) indicating direct involvement in mammary tumor progression [363]. Further, attenuation
of FAK function dramatically increased apoptosis in breast cancer cells [364]. Disruption of
FAK signaling by expressing the N-terminal domain FAK in human breast carcinoma cells has
led to rounding, detachment and apoptosis [365]. To gain insight into the influence of genistein
and daidazine in this important pathway in breast cancer, in vitro and in vivo studies have been
conducted. According to an in vitro study, the soy isoflavones genistein, daidzein and 17β
estradiol increased the number of focal adhesions and FAK activity in ERα +ve (T47D cells) as
well as in ERα -ve (MDA-MB-231) breast cancer cells indicating possible involvement of novel
signaling pathways and independent of estrogen receptors. Authors of this study suggested
a progressive role (to metastasis) for soy isoflavones in the activation of multiple FAK regulated
signaling pathways relevant to breast cancer [366], however the mechanism was not investi‐
gated. The studies of Mitra and co-workers may possibly explain the mechanism of FAK in
breast cancer metastasis [367]. According to this study, reduced FAK activity or expression
blocked 4T1 breast cancer cell invasion through matrigel and the blocking was associated with
a 2-3 fold reduction in the expression of urokinase plasminogen activator (uPA) [367]. uPA is
a serine protease that cleaves extracellulaer matrix and stimulate plasminogen to plasmin.
Cancer cells are known to digest the ECM via substances like uPA and matrix metalloproteases
(MMPs) as a means of invading surrounding tissue. This idea is supported by the fact that
breast cancer patients with higher level of MMP-9 in tissue is associated with lymph node
metastasis; thus, MMP-9 levels in serum, tumour tissue and urine are used as prognostic
markers [368]. Furthermore, a study on the role of membrane-type 1 matrix metalloproteinase
(MT1-MMP) in vitro and in SCID mice reports that the down regulation of mammary cancer
cell MT1-MMP has no effect on primary tumour growth and lymph node metastasis, but
reduces the occurrence of lung metastasis [369]. Interestingly, uPA secretion from mammary
carcinoma cells can be influenced by genistein. This property of genistein has been shown in
vitro and in vivo and the implication on tumour angiogenesis has been studied using F3II
mammary carcinoma cells in culture as well as in a syngeneic mouse model. Accordingly, non-
cytotoxic concentrations of genistein (0.1-50μM) significantly reduced motility in F3II mam‐
mary carcinoma cells and inhibited the secretion of uPA from cell monolayers. Once F3II cells
were implanted in syngeneic mice receiving a treatment of genistein (10mg/kg/day), anti
antiangiogenic effects were evident [357].
These studies indicate the effectiveness of genistein to inhibit angiogenesis and metastasis by
inhibiting proteolytic substances such as uPA. In this respect, our attempt to further explore
the value of soy isoflavones in modulating metastasis enabled us to review some important
findings. Studies by Shao et al, [1998] reported that genistein inhibited the invasion of MCF-7
and MDA-MB-231 cells in vitro and the inhibition was characterized by down regulation of
MMP-9 (matrix mettaloproteinase-9) and up regulation of TIMP-1 (tissue inhibitor of metta‐
loproteinase-1) [370]. The same effects were seen in nude mouse xenografts of MCF-7 and
MDA-MB-231 cells [371]. Furthermore, in MDA-MB-231 xenografts, genistein inhibited
tumour growth, stimulated apoptosis, regulated p21 WAF1/CIP1 expression, inhibited
angiogenesis with reduced vessel density and decreased the levels of vascular endothelial
growth factor and transforming growth factor β1 [370]. Further studies by the same authors
reported that genistein inhibits both constitutive and epidermal growth factor stimulated
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invasion in ER- human breast carcinoma cells as characterized by up regulation of TIMP-1 as
well as other trypsin inhibitors like protease nexin-II (PN-II) and alpha 1-antitrypsin (alpha 1-
AT) [371]. Kousidou et al [2005], examining normal mammary cells (MCF-12A), low invasive
(ER+ve) MCF-7 cells and high invasive MDA-MB-231 (ER-ve) cells (in parallel) showed
differences in the effect of genistein on highly invasive and low invasive cells. Accordingly,
all cell types expressed genes of MMP-2, MMP-9, membrane-type matrix metalloproteinase
(MT-1, MT-2, MT-3), MMP and TIMP-1, -2 and -3. However, once genistein was added, down
regulation of all MMP genes in highly invasive cells and down regulation of many genes in
low invasive MCF-7 cells was observed [372].
Based on the above findings, genistein has a role in reducing metastasis and this appears to
arise from its ability to suppress uPA and MMPs thereby invading barriers with no direct effect
on the capacity of cell mobility. According to the literature, expression of uPA and MMPs is
regulated by NFk-B [373] [307]. Therefore it would be worthwhile to review any association
between genistein and the NF-kB pathway.
9.1.1. Genistein may act via inhibition of the NF-ĸB pathway
The possible connection between NF-κB and breast cancer has been extensively studied [374].
Using a doxycycline-inducible new mouse model to inhibit NF-κB activity, specifically within
the mammary epithelium at the time of tumor development, Connelly et al (2011) indicated
the active contribution of NF-κB in mammary tumor progression [301]. In this model, inhibi‐
tion of NF-κB activity showed an increase in tumor latency and a decrease in tumor burden
[301]. Specifically, soy isoflavones inhibited the tumors by suppressing the NF-κB pathway.
Furthermore genistein potentiates the activity of a number of NF-κB mediated chemothera‐
peutic agents by increasing apoptosis in various cancer cells, including MDA-MB-231 breast
cancer cells [375]. In the same cell line, genistein induces G2/M cell cycle arrest via stable
activation of ERK1/2 pathway [354],[376]. Furthermore, the MDA-MB-231 cell line has the
ability to selectively block NF-κB transactivation of IL-6, a cytokine that is known for estrogen
independent tumorigenesis activity [377]. Inhibition of proteosome activity by genistein in
MCF-7 breast cancer cells has also been associated with NF-κB inhibition [378]. This property
of genistein is particularly important for ER deficient breast cancer as constitutive NF-ĸB and
Mitogen- and Stress- Activated Protein Kinase-1 (MAPK) /MSK activity are linked with
aggressiveness and the metastasis.
It is clear that almost all of the studies that show beneficial effects of soy isoflavones utilized
genistein. However, within the natural products of soy and soy food not only genistein, but
daidzein and glycitein are present. A recent study testing genistein, daidazine and glycitein
separately has indicated interesting results. According to this study, only genistein induced
apoptosis in MCF-7 breast carcinoma cells whereas daidzein caused a slight cell-stimulating
effect in the absence of E2; thus, the authors pointed toward the possible risk of breast cancer
in postmenopausal women who take soy supplements [379]. This statement is important as a
number of soy supplements available in the market contain high levels of daidzein [380, 381].
An animal study using nude mice and MDA-MB-435 breast cancer cells reported the individual
and combined soy isoflavones exerting differential effects on metastatic cancer progression
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[382]. As described in this study, daidazine increased mammary tumour growth by 38% while
genistein decrease tumor growth by 33%. Moreover, the combined isoflavones increased
metastasis to all the organs examined, although no effect on primary tumour growth was
noted. These results have led authors to include the consumption of soy foods as a cause of
increased breast cancer metastasis. Also, a number of studies by Ju et al [383-385] have cited
enhanced growth effects of soy components in ER+ve breast cancers. However, with these
studies conducted in immune compromised mice, the relevance of these findings have been
criticized [386], especially as pre-treatment with genistein has shown to been protective against
mammary tumors [387]. More recently, the antiproliferative activity of both genistein and
quercetin has been indicated in the prevention and treatment of HER2-overexpressing breast
cancer via inhibition of NFκB signaling [388]. In this study, these specific phytoestrogens
inhibited proliferation in MCF-7 cell lines accompanied by an increase in intrinsic apoptotic
indicators, induction of the extrinsic apoptosis pathway (up-regulating p53), a reduction in
the phosphorylation level of IκBα, and negated the nuclear translocation and subsequent
phosphorylation of nuclear p65 [388].
9.1.2. Sources of soy
Soybeans can be considered as the richest source of isoflavones in the human diet [389, 390],
and are available in fermented and non-fermented forms. Fresh green soy beans, whole dry
soybeans, whole-fat soy flour, soy milk and soymilk products such as tofu, okara and yuba
are non-fermented while soy sauce, temphe, miso and natto are fermented products [391].
Additionally, products such as soy dairy substitutes, soy cheese, soy yogurt, and soy burgers
seem to be popular in Western countries. The isoflavone content in various soy-based food
products greatly differ. Other than soy food products, soy supplemented (categorized as a
class of complementary medicine) nutraceuticals are widely consumed by Western commun‐
ities. The quality and standard of these supplements are questionable. For instance, a survey
carried out in the Eastern Washington Region of U.S.A. tested 13 products (7 tablet and 6
capsule formulations) by HPLC and showed that only 4 of the 13 products contained the
minimum of 90% isoflavone content claimed on the label and variations in composition over
time were noted [392]. Interestingly, a recent review shows that overall, most commercially
available nutraceuticals are poor in quality [393].
9.1.3. Clinical studies
Although there have been a large number of studies carried out to evaluate a possible soy-
breast cancer link, evidence is inconclusive. The two main theories tested involve the effect of
soy isoflavone consumption in risk of breast cancer incidence and its effect on recurrence. The
largest population based cohort study, including 5,042 female breast cancer survivors, shows
that soy food consumption is significantly associated with decreased risk of death and
recurrence [394]. Another cohort of 1,954 female breast cancer survivors, who consumed soy
isoflavones at the levels comparable to the Asian population, while undergoing tamoxifen
therapy showed a reduction in the risk of cancer recurrence and no interference in the efficacy
of tamoxifen [395]. Further studies have indicated that soy intake prior to cancer diagnosis is
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unrelated to disease-free breast cancer survival and that the association between soy protein
intake and breast cancer survival does not differ according to the presence of other risk factors
such as ER/PR status, tumor stage, age at diagnosis, body mass index (BMI), waist to hip ratio
(WHR), or stage of menopause [396]. No variations were noted in the soy-survival association
of indicated polymorphisms in ERα and ERβ indicating that soyfoods do not have an adverse
effect on breast cancer survival. A recent meta-analysis by Dong and Qin (4 studies of breast
cancer recurrence and 14 studies of breast cancer incidence) revealed that the consumption of
soy isoflavone is inversely associated with risk of breast cancer incidence [397]. However, the
protective effect is only observed among studies conducted in Asian populations, unlike those
reported in Western populations [397]. One of the previous meta-analysis studies by Wu et
al [2008] show a similar trend. Accordingly, in Asian populations a higher intake of soy
isoflavones, as compared with lower intake, is associated with 29% reduction in the risk of
developing breast cancer [398]. Hence, the consumption of soy food at levels similar to those
consumed by Asian populations may have protective effects. However, there is evidence in
the literature to show possible adverse effects of soy due to its known stimulatory effect on
the premenopausal female breast as indicated by increased secretion of breast fluid, the
appearance of hyperplastic epithelial cells and elevated levels of plasma estradiol [399]. Some
animal studies support the idea of related disadvantages of consuming soy isoflavones. In
overiectomized athymic nude mice, physiological concentrations of dietary genistein stimu‐
lates the growth of estrogen dependent MCF-7 tumors in a dose dependent manner [383,
400]. Furthermore, the same test model showed that dietary genistein reverses the inhibitory
effect of tamoxifen on the growth of MCF-7 tumors [384].
9.2. The role of curcumin and piperine in breast cancer prevention and its effects on normal
human breast stem cell renewal and signaling
Curcumin is a plant derived polyphenol which gives rise to the yellow colour in the spice,
tumeric. This pigment is obtained from the plant Curcuma longa and has been noted to have
power against cancer. In their review of the mechanisms of cell cycle regulation by curcumin,
Gaurisankar and Das have named it as a multiple edged sword [401] because of its ability to
regulate the cell cycle as well as apoptosis. Distorted cell cycle regulation and programmed
cell death/apoptosis are characteristic features of cancer and curcumin has been shown to
target both mechanisms. The ability of curcumin to inhibit telomerase activity [402] and to
disrupt mitotic spindle structure causing [403] micronucleation in MCF-7 breast carcinoma
cells has been reported. Also, curcumin is known to induce anti-proliferative activity via the
decreased expression of cyclin D1 and CDK-4 in MCF-7 breast carcinoma cells [404] and can
induce apoptosis through p53 dependent Bax induction [405]. Curcumin is able to disrupt
breast tumor growth, but also to inhibit metastasis.
As with genestein, curcumin has been shown to mediate its anti-cancer effects via regulation
of the NF-κΒ signaling pathway. In the nude mouse model, curcumin suppresses the pacli‐
taxel-induced NF-κΒ pathway resulting in the inhibition of lung metastasis of human breast
cancer [406]. The modification of NF-kB signaling eventually leads to pro-apoptotic events and
perhaps inhibition of ECM breakdown. Curcumin induced apoptosis in MDA-MB-231 cells
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in vitro is associated with IkB and p65 phosphorylation and hence reduced activation of NFkB
[407]. This leads to reduced expression on MMPs, diminished invasion through a reconstituted
basement membrane and a lower number of metastases in immunodeficient mice injected with
tumor cells via intra cardiac route [407]. The high level of of MMP-3 expression noted in MDA-
MB-231 invasive breast carcinoma cells is not evident on MCF-7 non-invasive breast cancer
cells, implicating its importance in invasion and metastasis. The possibility of using the major
forms of curcuminoids, curcumin, demethoxycurcumin, and bisdemethoxycurcumin (all of
which are found in turmeric powder) as MMP-3 inhibitors to modulate MMP-3 expression has
been suggested [408]. According to Chiu and Su (2009), curcumin inhibits proliferation by
increasing the Bax to Bcl-2 ratio while inhibiting the migration via decreasing NF-kB p65
expression in breast cancer MDA-MB-231 cells [409]. Utilizing microarray gene expression
analysis on MDA-MB-231 breast cancer cells, Bachmeier et al. demonstrated the ability of
curcumin to downregulate inflammatory cytokines CXCL-1 and -2 via suppression of NF-κB
translocation. Moreover, silencing CXCL-1 and -2 resulted in a downregulation of several
metastasis promoting genes [410].
Interestingly, curcumin can interfere with estrogen-mimicking pesticides such as endosul‐
fane, DDT and chlordane [411].
9.2.1. Sources of curcumin
Curcumin is generally considered to be the most active component and the principal curcumi‐
noid found in tumeric [411]. The spice tumeric is commonly used in curries and contains 2-8%
of this active ingredient [412], however a supplement form is also available.
9.2.2. Clinical trials
Little data is available on the pharmacokinetics and metabolism of curcumin in humans. Dose-
limiting toxicity is not reported and high oral doses of curcumin (up to 12g/day) have been
tested [220, 413, 414]. In a phase one clinical trial involving individuals with non-invasive
cancer and pre-cancerous conditions, oral dosing of 4g, 6g and 8g of curcumin yielded peak
serum concentrations of 0.51 +/- 0.11microM, 0.63 +/- 0.06 microM, and 1.77 +/- 1.87 microM,
respectively. Peak serum concentrations of curcumin are seen 1-2 hours after oral intake and
this gradually declines within 12 hours [220]. In another phase I clinical trial involving 15
patients with advanced colorectal cancer, 3.6g of curcumin daily for up to 4 months was well-
tolerated [413]. Another study examined the pharmacokinetics of 450mg-3600mg curcumin
(daily for 1 week) in twelve patients with hepatic metastatic disease from primary colorectal
adenocarcinomas. Using a high-performance liquid chromatography assay, low nanomolar
levels of the parent compound and its glucuronide and sulphate conjugates were found in the
peripheral or portal circulation; despite its absence in liver tissue, trace levels of products of
its metabolites were detected [415]
Due to the poor bioavailability of curcumin systemically, high priority has been given to study
its potential against colorectal cancers. A very recent publication on a phase IIa clinical trial
involving men and women 40 years of age or over and smokers that carry 8 or more colorectal
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aberrant crypt foci (ACF) indicates that oral dosing of curcumin (4g per day for 30 days)
significantly reduces colorectal ACF, a biomarker of colon carcinogenesis. [416] The reported
anti-carcinogenic effect of curcumin is not associated with increased levels of curcumin in local
tissue but increased levels of conjugate concentrations in suggesting that curcumin may
mediate its effects by cuccumin conjugates delivered systemically. The same study showed
that the presence of curcumin conjugates in plasma and tissue prior to treatment (believed to
be originated from the normal diet of the studied population) were accompanied by a steady
increase of curcumin conjugates following the month-long daily dosing [416]. A study
examining the pharmacokinetics of curcumin at the concentrations of 10g and 12g in twelve
healthy volunteers indicates comparable results. Accordingly, a single dose of orally admin‐
istered curcumin resulted in the detection of conjugates, glucuronides and sulfates in plasma
in all subjects while free curcumin was evident in only one subject [414]. Even though curcumin
conjugates and other breakdown products have not been assessed for their anticarcinogenic
properties [416], these findings shed some light on the potential of curcumin as a treatment of
all cancers, including those of colorectal origin. This may offer a likely explanation of how
continuous exposure to small quantities of curcumin via normal diets protects Asian women
from breast cancer.
A phase I dose escalation trial of combined effects of docetaxel and curcumin in patients with
advanced and metastatic breast cancer was published very recently. This study involved 14
patients and demonstrated the feasibility, safety and tolerability of a combination of curcumin
with a standard dose of docetaxel which warrants further investigation and progression to a
Phase II clinical trial [417]. Similarly, the curcumin inhibiting effects of chemotherapy induced
apoptosis in models of human breast cancer have been identified [418].
9.2.3. Curcumins’ ability to destroy cancer stem cells
The properties of CSC’s are connected with major signaling pathways. The signaling pathways
active in mammary stem cells are shown to be Wnt/β catenin, Hh and Notch [60],[51],[185],
[206],[269].
A recent study by Karkarala et al. has demonstrated the potent inhibitory effect of curcumin
and piperine on Wnt/β-catenin signaling in primary human breast epithelial cells [419]. In this
study, inhibition of Wnt signaling pathway was shown to affect breast stem cell renewal by
inhibiting the mammosphere formation. According to the authors, curcumin and piperine
(separately and in combination) inhibited breast stem cell self-renewal; however toxicity to
differentiated cells was not reported. The plasma concentration of curcumin in people taking
high oral doses has been shown to be very low due to many reasons such as metabolism of the
compound in the intestine and the liver, as reviewed by Burgos-Moron et al. [420].
The lack of bioavailability of curcumin was known as a potential disadvantage for years and
various strategies have been investigated to overcome the problem. One such strategy has been
the use of piperine in combination of curcumin. Accordingly, concomitant administration of
piperine and curcumin tends to increase the bioavailability (up to 2000%) compared to
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administration of curcumin alone in an experimental group of people [421]. This finding could
well be a possibility as piperine has been shown to inhibit P-glycoproteins and CYP3A4
expressed in enterocytes where the bioavailability of many orally ingested compounds are
determined [422]. Alternatively, increasing the solubility of curcumin by heat as means of
increasing the bio availability has been suggested [423]. This method is easily achievable and
a well-cooked curry with tumeric and piperine could be a tasty way of obtaining the goodness
of these natural compounds.
Based on the ability of curcumin and piperine to inhibit CSC’s as described above, curcumin
has great potential as a possible therapeutic agent against breast cancer. The majority of the
breast cancer patients have tumors that respond to the naturally occurring hormone, estrogen.
Therefore, most of the currently available drugs known to be effective against breast cancer
can prevent the action of estrogen and are thus referred to as selective estrogen receptor
modulators (SERM). Unfortunately, there is a cohort of patients whose tumours do not express
estrogen receptor. SERMs are of no use for this group with ER -ve breast cancers. The potential
of curcumin and piperine to suppress the self-renewal of stem cells could prove beneficial in
ER +ve as well as ER -ve breast cancer patients.
10. Summary
Considering the existence of CSC’s in breast cancer, and the inability of current therapeutic
approaches to destroy such, we propose targeting CSC’s as a tool to investigate the effect of
natural dietary compounds. Specifically, we suggest isolates of soy and turmeric, and their
effects on breast cancer tumors and metastasis reoccurrence in breast cancer. Similar to other
developmental agents aimed at cancer signaling pathways, the optimal dosing, dosing
regimens and adverse effects will have to be refined. However, these prospects are notably
different than conventional therapeutics in several ways and such should be contemplated
upon exploring such molecules. For example, consider the complex cross-talk of both inter-
and intra-cell signaling pathways and how feedback mechanism effects may eliminate
inhibitors via the actions of a single pathway. Figure 2 summarizes targeted areas of interrup‐
tion via the major pathways involved in stem cell renewal as well as those pathways that may
be responsible for downstream signaling to these major pathways. Additionally, if CSC’s are
primary targets, then metastasis incidence and/or cancer free survival may be a more appro‐
priate efficacy endpoint in clinical trials than tumor volume. Perhaps then it would be more
strategic in breast cancer to design preclinical trials based on incorporating combination
regimens at the early stages of drug development while targeting multiple pathways and
focusing on appropriate endpoints; all to avoid missing potentially important therapeutic
benefits. While plant based derivatives, such as those considered in this chapter hold promise
in breast cancer treatment and management, their development should be pursued systemat‐
ically, guided by sound scientific principles.
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Figure 2. (Tobin, GA, 2012) An Overview of the Major Signaling Networks Involved in Breast Cancer and CSC Self-re‐
newal, including Notch, NFκB, Wnt and Hh. Symbols and acronyms have been discussed previously, with the exception
of P = phosphorylation, BAD = Bcl-2-associated death promoter, and SHH = Sonic Hh. Also, NUMB references the Pro‐
tein numb homolog that in humans is encoded by the NUMB gene.
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